Pharmaceutical composition having improved bioavailability of pranlukast, and preparation method therefor
A pharmaceutical composition with pranoxetine, water-soluble polymer, and silica-based glidant, prepared via a solvent-free method, addresses bioavailability challenges, achieving equivalent efficacy at lower doses and reducing side effects.
Patent Information
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- DASHAN PHARMACEUTICAL CO LTD
- Filing Date
- 2026-05-27
- Publication Date
- 2026-07-10
AI Technical Summary
Existing methods for improving the bioavailability of pranoxetine, a poorly soluble drug, face challenges such as high manufacturing costs, complex equipment requirements, environmental pollution risks, and side effects from high-dose administration, necessitating a novel formulation and preparation method.
A pharmaceutical composition comprising 15 to 25 parts by weight of pranoxetine, 0.1 to 10 parts by weight of a water-soluble polymer, and 0.1 to 5 parts by weight of a silica-based glidant, prepared through a method involving mixing with a diluent and disintegrant, followed by kneading with a water-soluble polymer and solubilizer in water and ethanol, respectively, without using organic solvents.
The composition enhances solubility and bioavailability, allowing a reduced dosage of pranoxetine to 50 mg per tablet, equivalent to or better than commercially available formulations, improving patient compliance and reducing side effects.
Smart Images
Figure 00000000_0000_ABST